RXRX — Recursion Pharmaceuticals, Inc. stock price, charts and financials

Latest market price

3.83

+0.29+8.19%

Overview Short InterestFilings

RXRXQT56Recursion Pharmaceuticals, Inc.·NASDAQ

Overview Short InterestFilings

3.83+8.19%

News

Up 8.2% — Recursion Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript (Benzinga).

Medium confidence

Loading chart...

Signal & projected range

Short-squeeze setupHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

GPCR-0.28%$35.00 ZBIO-1.47%$31.50 NUVB-3.62%$5.85 AGIO-1.61%$33.07 KOD-0.43%$32.71 VCEL-0.03%$40.02 CMPS+1.27%$15.19 BHVN-1.94%$13.62

Snapshot

Index	-	P/E	-	EPS (ttm)	-1.04	Insider Own	4.56%	Shs Outstand	524.68M	Perf Week	19.69%

Market Cap	2.01B	Forward P/E	-	EPS next Y	-0.89	Insider Trans	-2.02%	Shs Float	408.73M	Perf Month	9.43%

Enterprise Value	1.53B	PEG	-	EPS next Q	-0.24	Inst Own	-	Short Float	43.83%	Perf Quarter	18.58%

Income	-511.22M	P/S	36.63	EPS this Y	13.71%	Inst Trans	-	Short Ratio	9.02	Perf Half Y	13.65%

Sales	54.85M	P/B	2.23	EPS next Y	0.36%	ROA	-42.79%	Short Interest	179.15M	Perf YTD	-6.36%

Book/sh	-	P/C	-	EPS next 5Y	-	ROE	-50.41%	52W High	7.18 -46.66%	Perf Year	-18.68%

Cash/sh	-	P/FCF	-	EPS past 3/5Y	-	ROIC	-48.34%	52W Low	2.77 38.27%	Perf 3Y	-55.47%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	23.31% 90.37%	Gross Margin	-46.66%	Volatility	7.49% 5.92%	Perf 5Y	-86.46%

Dividend TTM	-	EV/Sales	27.81	EPS Y/Y TTM	38.46%	Oper. Margin	-991.72%	ATR (14)	0.21	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	5.03	Sales Y/Y TTM	-6.78%	Profit Margin	-945.92%	RSI (14)	62.16	Recom	2.60

Dividend Gr. 3/5Y	-	Current Ratio	5.03	EPS Q/Q	39.02%	SMA20	12.66%	Beta	1.05	Target Price	5.30

Payout	0.00%	Debt/Eq	0.07	Sales Q/Q	-57.89%	SMA50	17.51%	Rel Volume	2.31	Prev Close	3.54

Employees	600	LT Debt/Eq	0.05	Earnings	Nov 04	SMA200	6.21%	Avg Volume	19.13M	Price	3.83

IPO Date	Apr 16, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-4.17% -33.42%	Net Debt/EBITDA	1.09	Volume	44,208,549	Change	8.19%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Aug-17-26	Reiterated	Morgan Stanley	Equal Weight	$5.50 → $5.30
May-14-26	Reiterated	Morgan Stanley	Equal Weight	$11 → $5.50
Dec-17-25	Reiterated	UBS		$11
Dec-17-25	Reiterated	Morgan Stanley	Equal Weight	$11
Dec-17-25	Upgrade	JP Morgan	Neutral → Overweight
Feb-28-25	Reiterated	Leerink Partners	Market Perform	$6.00
Sep-04-24	Reiterated	Needham	Buy	$11
Sep-03-24	Reiterated	KeyBanc	Overweight	$12
Sep-03-24	Reiterated	Jefferies	Hold	$6.00
Jun-26-24	Reiterated	KeyBanc	Overweight

Latest News· Times ET

Sep-17-26

Sep-17-2605:22AM

Recursion Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call TranscriptBenzinga

Sep-16-26

Sep-16-2602:51PM

Recursion Pharmaceuticals (RXRX) Falls More Steeply Than Broader Market: What Investors Need to Knowzacks.com

Sep-15-26

Sep-15-2609:01AM

Recursion Pharmaceuticals, Inc. (RXRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcriptseekingalpha.com

Sep-10-26

Sep-10-2602:50PM

Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Todayzacks.com

Sep-08-26

Sep-08-2610:00AM

2 Beaten-Down Stocks to Avoid Right Nowfool.com

Sep-05-26

Sep-05-2607:00AM

Oracle, Adobe Results In Focus As Earnings Season Winds DownSeekingAlpha

Sep-04-26

Sep-04-2608:37AM

Why Is Recursion Pharmaceuticals (RXRX) Up 8.2% Since Last Earnings Report?zacks.com

Sep-03-26

Sep-03-2610:10AM

The Market Just Told You Which Layer Of AI Biology It Is Paying Forglobenewswire.com

07:35AM

Can RXRX's Pipeline Expansion Strengthen Its Long-Term Growth Outlook?zacks.com

Aug-20-26

Aug-20-2604:00AM

Tempus AI Just Had Their Entire Strategy Validated By Moderna's Vaccine AdvanceSeekingAlpha

Aug-17-26

Aug-17-2607:01AM

4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharmazacks.com

Aug-16-26

Aug-16-2609:03PM

Recursion Pharmaceuticals Highlights AI Platform, Roche Progress and Pipeline Updatesdefenseworld.net

Aug-13-26

Aug-13-2604:00AM

Jim Cramer: These Utilities Stocks Are 'Oversold,' Fastly 'Back From The Abyss'Benzinga

Aug-12-26

Aug-12-2611:50PM

Recursion Pharmaceuticals, Inc. $RXRX Stake Increased by California State Teachers Retirement Systemdefenseworld.net

Aug-11-26

Aug-11-2612:47PM

Recursion Pharmaceuticals, Inc. (RXRX) Presents at Bank of America SMID Cap Virtual Conference Transcriptseekingalpha.com

Company

Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering. Their developmental pipeline features several clinical-stage compounds: REC-994, which is advancing through Phase IIa trials for cerebral cavernous malformation; REC-3599, currently in Phase I trials for GM2 gangliosidosis; REC-2282, aimed at treating neurofibromatosis type 2; and REC-4881, intended for familial adenomatous polyposis. Beyond these, Recursion maintains a comprehensive preclinical portfolio. This includes REC-3964 for Clostridium difficile colitis, REC-64917 targeting neural or systemic inflammation, and REC-65029 for HRD-negative ovarian cancer. Further preclinical candidates are REC-648918, designed to enhance anti-tumor immunity; REC-2029 for wnt-mutant hepatocellular carcinoma; REC-14221 for various solid and hematological malignancies; and REC-64151, focused on addressing immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has established strategic collaborations and agreements with partners such as Bayer AG, the University of Utah Research Foundation, the Ohio State Innovation Foundation, Chromaderm, Inc., and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019
Total Revenue	55	75	59	—	—	—	—	—
Cost of Goods Sold Incl. D&A	80	121	45	—	—	—	—	—
Gross Profit	-25	-46	14	—	—	—	—	—
Selling, General and Administrative Excl. Other	153	177	178	—	—	—	—	—
Research and Development	382	425	314	—	—	—	—	—
Other Operating Expense	-17	0	1	—	—	—	—	—
Operating Income	-544	-648	-479	—	—	—	—	—
Interest Expense	1	2	2	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	22	5	16	—	—	—	—	—
Net Income Before Taxes	-523	-645	-465	—	—	—	—	—
Income Taxes	-5	0	-1	—	—	—	—	—
Consolidated Net Income	-519	-645	-464	—	—	—	—	—
Net Income From Continuing Operations	-519	-645	-464	—	—	—	—	—
Net Income	-519	-645	-464	—	—	—	—	—
EPS (Recurring)	-1.04	-1.44	-1.69	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	-1.04	-1.44	-1.69	—	—	—	—	—
EPS (Diluted)	-1.04	-1.44	-1.69	—	—	—	—	—
EBITDA	-445	-559	-427	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—
Price To Sales Ratio	37.05	24.38	31.39	—	—	—	—	—
Gross Margin	-45.45	-61.33	23.73	—	—	—	—	—
Operating Margin	-989.09	-864.00	-811.86	—	—	—	—	—
Net Margin	-943.64	-860.00	-786.44	—	—	—	—	—
Shares Outstanding	532	447	274	—	—	—	—	—
Market Capitalization	2,038	1,828	1,852	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Khan Najat	CEO and President	Sep 08 '26	Sale	3.52	22,408	78,822	2,072,890	Sep 10
Borgeson Blake	Director	Sep 01 '26	Sale	3.34	30,000	100,200	6,158,287	Sep 02
Borgeson Blake	Director	Aug 04 '26	Sale	3.25	30,000	97,500	6,188,287	Aug 06
Borgeson Blake	Director	Jul 07 '26	Sale	3.96	40,000	158,500	6,218,287	Jul 09
Bumpus Namandje	Director	Jun 18 '26	Sale	3.18	3,963	12,602	127,632	Jun 22
Gibson Christopher	Director	Jun 05 '26	Sale	3.62	40,000	144,800	883,735	Jun 05
Khan Najat	CEO and President	Jun 05 '26	Sale	3.58	23,588	84,459	2,175,796	Jun 05
Bumpus Namandje	Director	Jun 03 '26	Sale	3.54	4,386	15,526	43,171	Jun 04
Borgeson Blake	Director	Jun 02 '26	Sale	3.68	30,000	110,400	6,169,863	Jun 04
Gibson Christopher	Director	May 22 '26	Sale	3.08	40,000	123,200	883,735	May 27
Gibson Christopher	Director	May 07 '26	Sale	3.37	40,000	134,800	926,556	May 08
Borgeson Blake	Director	May 05 '26	Sale	3.52	30,000	105,600	6,199,863	May 07
Gibson Christopher	Director	Apr 22 '26	Sale	3.61	40,000	144,400	906,556	Apr 24
Gibson Christopher	Director	Apr 07 '26	Sale	3.10	40,000	124,000	906,556	Apr 08
Borgeson Blake	Director	Apr 07 '26	Sale	3.10	30,000	93,000	6,229,863	Apr 08

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.